Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Business Segments — Interest Income

Similar metrics at other companies

Anterix logo
ATEXReportable Segment — Interest Income
$472K+5.8%
Marqeta logo
MQReportable Segment — Interest Income
$5.36M-48.9%
Tarsus Pharmaceuticals, Inc. logo
TARSReportable Segment — Interest Income
$3.7M-12.6%
Exelixis logo
EXELReportable Segment — Interest Income
$14.21M-15.4%
Century Aluminum logo
CENXReportable Segment — Interest Income
$4.4M+132%
Douglas Elliman logo
DOUGOne Reportable Segment — Interest Income
$890K-34.6%

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M
CapEx$158.0K+103%
Free cash flow$12.5M

Valuation

See full
Market cap$3.32B+81.4%
Enterprise value$3.4B+82.1%
P/S7.2×+0.2×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001787306-26-000051
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other segment expenses(1)6,2955,50912,15612,694
Total operating expenses113,43296,115227,919186,490
Operating income (loss)16,429(14,611)7,340(39,140)
Interest income2,2792,0764,5544,613
Interest expense(3,406)(3,029)(7,774)(6,011)
Other income (expense), net(157)20(177)213
Provision for income taxes136342229621
Segment and consolidated net income (loss)$15,009$(15,886)$3,714$(40,946)

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s business segments — interest income?
Arcutis Biotherapeutics, Inc. (ARQT) reported business segments — interest income of $2.28M in Q2 2026.
How has Arcutis Biotherapeutics, Inc.'s business segments — interest income changed year-over-year?
Arcutis Biotherapeutics, Inc.'s business segments — interest income increased by 9.8% year-over-year, from $2.08M to $2.28M.
What does business segments — interest income mean?
Represents the income earned from cash balances, short-term investments, or other interest-bearing assets held by the segment. This reflects the segment's ability to generate returns on its liquid capital reserves.

Ask your AI about Arcutis Biotherapeutics, Inc.'s business segments — interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude